Pro-Dex, Inc. Announces Fiscal 2020 Second Quarter and Six-Month Results

health news

IRVINE, CA / ACCESSWIRE / February 6, 2020 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2020 second quarter ended December 31, 2019. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2020 with the Securities and Exchange Commission today.

Quarter Ended December 31, 2019

Net sales for the three months ended December 31, 2019, increased $1.6 million, or 24%, to $8.0 million from $6.4 million for the three months ended December 31, 2018, due primarily to increased repair revenue generated from our largest customer.

Gross profit for the three months ended December 31, 2019, increased $615,000, or 27%, to $2.9 million from $2.2 million for the same period in fiscal 2019, due to the increase in sales described above and our ability to better absorb and maintain the level of our fixed manufacturing costs.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2019, increased $140,000, or 13%, to $1.2 million compared to the prior fiscal year’s corresponding quarter, reflecting our planned investments in research and development, selling, and general and administrative expenses in an effort to release new products and garner new customer relationships.

Net income for the quarter ended December 31, 2019, was $1.2 million, or $0.31 per diluted share, compared to $1.2 million, or $0.28 per diluted share, for the corresponding quarter in fiscal 2019.

Six Months Ended December 31, 2019

Net sales for the six months ended December 31, 2019, increased $1.9 million, or 14%, to $15.2 million from $13.3 million for the six months ended December 31, 2018, due primarily to increases in repair revenue generated from our largest customer.

Gross profit for the six months ended December 31, 2019, increased $669,000, or 13%, compared to the same period in fiscal 2019 due to the increase in sales described above.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the six months ended December 31, 2019, increased 21% to $2.5 million from $2.1 million in the prior fiscal year’s corresponding period, reflecting our planned investments in research and development, selling, and general and administrative expenses in an effort to release new products and garner new customer relationships.

Net income for the six months ended December 31, 2019 was $2.4 million, or $0.58 per diluted share, compared to $2.5 million, or $0.59 per diluted share, for the corresponding period in fiscal 2019.

CEO Comments

Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer, commented, “We are pleased with our second quarter and year-to-date results and our net sales growth.” Mr. Van Kirk continued, “We expect the momentum to continue. Additionally, we are pleased that the private-labeled thoracic driver and related accessories are on track to ship in our third quarter of this fiscal year.”

The amount spent on projects under development as well as the estimated market launch date and estimated future annual revenue is summarized below (in thousands):

 
  Three and Six Months ended December 31, 2019     Three and Six Months ended December 31, 2018     Market Launch     Est Annual Revenue  
Total Research & Development costs:
  $ 397     $ 881   $ 326     $ 735              
 
                                         
Products in development:
                                         
Thoracic Driver
  $ 17     $ 37   $ 33     $ 107       03/20     $ 4,000  
Arthroscopic Shaver(1)
    3       11     38       60       06/21     $ 600  
ENT Shaver
    66       155                 01/21     $ 2,000  
Arthroscopic Attachment
              9       16       (2)     $ 150  
CMF Driver
    29       46     2       3       06/20     $ 350  
Sustaining & Other
    282       632     244       549                  
Total
  $ 397     $ 881   $ 326     $ 735                  
 
                                             
Customer CMF Driver (3)
  $ 81     $ 181   $     152     $ 217       06/20     $ 2,500  

(1)This project has been internally pushed back to focus on our new internal Pro-Dex branded ENT shaver.
(2)Internal development of this project is now complete, but we are looking for the most attractive sales channel.
(3)Costs incurred related to customer contracts are included in costs of sales and deferred costs and are not included in research and development costs.

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors to a wide range of industries. Pro-Dex’s products are found in hospitals and medical engineering labs around the world. For more information, visit the Company’s website at www.pro-dex.com.

Statements herein concerning the Company’s plans, growth, and strategies may include ‘forward-looking statements’ within the context of the federal securities laws. Statements regarding the Company’s future events, developments, and future performance, (including, but not limited to, estimated product launch dates and estimated future revenue), as well as management’s expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company’s actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company’s filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC.
CONDENSED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)

             
 
  December 31,
2019
   
June 30,
2019
 
ASSETS
           
Current Assets:
           
Cash and cash equivalents
  $ 6,175     $ 7,742  
Investments
    3,540       2,649  
Accounts receivable, net of allowance for doubtful accounts of $17 and $0 at December 31, 2019 and at June 30, 2019, respectively
    2,683       4,100  
Deferred costs
    492       430  
Inventory
    7,808       6,239  
Prepaid expenses and other current assets
    193       623  
Total current assets
    20,891       21,783  
Equipment and leasehold improvements, net
    2,768       2,726  
Right of use asset, net
    3,107        
Intangibles, net
    145       129  
Deferred income taxes, net
    163       260  
Investments
    1,610       582  
Other assets
    42       40  
Total assets
  $ 28,726     $ 25,520  
 
               
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
Current Liabilities:
               
Accounts payable
  $ 1,672     $ 1,996  
Accrued expenses
    1,287       1,437  
Deferred revenue
    360       215  
Note payable and capital lease obligations
    633       622  
Total current liabilities
    3,952       4,270  
Deferred rent
          146  
Lease liability, net of current portion
    2,937        
Income taxes payable
    352       162  
Notes and capital leases payable, net of current portion
    3,613       3,934  
Total non-current liabilities
    6,902       4,242  
Total liabilities
    10,854       8,512  
 
Shareholders’ equity:
               
Common shares; no par value; 50,000,000 shares authorized; 3,884,098 and 4,039,491 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively
    13,634       15,815  
Accumulated other comprehensive income (loss)
    100       (549 )
Retained earnings
    4,138       1,742  
Total shareholders’ equity
    17,872       17,008  
Total liabilities and shareholders’ equity
  $ 28,726     $ 25,520  
 
               

PRO-DEX, INC.
CONDENSED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
(Unaudited)
(In thousands, except per share amounts)

             
 
  Three Months Ended
December 31,
    Six Months Ended
December 31,
 
 
  2019     2018     2019     2018  
 
                       
Net sales
  7,961     6,399     15,201     13,314  
Cost of sales
    5,097       4,150       9,557       8,339  
Gross profit
    2,864       2,249       5,644       4,975  
 
                               
Operating (income) expenses:
Selling expenses
    135       97       277       130  
General and administrative expenses
    664       633       1,327       1,197  
Gain from disposal of equipment
                      (7 )
Research and development costs
    397       326       881       735  
Total operating expenses
    1,196       1,056       2,485       2,055  
 
                               
Operating income
    1,668       1,193       3,159       2,920  
Interest expense
    (63 )     (69 )     (122 )     (89 )
Interest and other income
    33       93       68       168  
Gain on sale of investments
          356             356  
 
                               
Income from operations before income taxes
    1,638       1,573       3,105       3,355  
Income tax expense
    (389 )     (394 )     (751 )     (827 )
Net income
  1,249     1,179     2,354     2,528  
Other comprehensive income (loss), net of tax:
Unrealized income (loss) from marketable equity investments
    705       (494 )     649       (349 )
Comprehensive income
  1,954     685     3,003     2,179  
 
                               
Basic net income per share:
                               
Net income
  0.32     0.28     0.59     0.59  
Diluted net income per share:
                               
Net income
  0.31     0.28     0.58     0.59  
 
                               
 
                               
Weighted average common shares outstanding:
                               
Basic
    3,950       4,195       3,979       4,263  
Diluted
    4,053       4,242       4,082       4,303  
Common shares outstanding
    3,884       4,143       3,884       4,143  
                                 

PRO-DEX, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)

 
  Six Months Ended
December 31,
 
 
  2019     2018  
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net income
  2,354     2,528  
Adjustments to reconcile net income to
net cash provided by operating activities:
               
Depreciation and amortization
    282       195  
Gain from disposal of equipment
          (7 )
Share-based compensation
    19       18  
Non-cash lease expense
    22        
Amortization of loan fees
    4        
Gain on sale of investments
          (356 )
Deferred income taxes
    97       742  
Bad debt expense (recovery)
    17       (13 )
Changes in operating assets and liabilities:
               
Accounts receivable and other current receivables
    1,400       (838 )
Deferred costs
    (62 )     (143 )
Inventory
    (1,569 )     (147 )
Prepaid expenses and other assets
    430       (46 )
Accounts payable and accrued expenses
    (771 )     (301 )
Deferred revenue
    145       (1 )
Income taxes payable
    190       (123 )
Net cash provided by operating activities
    2,558       1,508  
 
               
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchases of investments
    (1,271 )     (1,365 )
Purchases of equipment and leasehold improvements
    (317 )     (540 )
Proceeds from sale of investments
          1,905  
Proceeds from sale of equipment
          7  
Increase in intangibles
    (23 )     (14 )
Net cash used in investing activities
    (1,611 )     (7 )
 
               
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Repurchases of common stock
    (2,215 )     (2,560 )
Proceeds from exercise of options and ESPP contributions
    15       17  
Payment of employee payroll taxes on net issuance of common stock
          (101 )
Proceeds from Minnesota Bank & Trust long-term debt, net of fees
          4,942  
Principal payments on notes payable and capital lease
    (314 )     (116 )
Net cash provided by (used in) financing activities
    (2,514 )     2,182  
 
               
Net increase (decrease) in cash and cash equivalents
    (1,567 )     3,683  
Cash and cash equivalents, beginning of period
    7,742       5,188  
Cash and cash equivalents, end of period
  6,175     8,871  
 
               

Contact:

Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200

SOURCE: Pro-Dex, Inc.

View source version on accesswire.com:
https://www.accesswire.com/575434/Pro-Dex-Inc-Announces-Fiscal-2020-Second-Quarter-and-Six-Month-Results